Clinical Trial Update: A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 study of a pemetrexed/cisplatin/gefitinib combination in Asian non-smoking patients with non-small cell lung cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• CISPLATIN (cisplatin)
• Iressa (gefitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-04-03